VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE : revenue, balance sheet and financial ratios

VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE is a French company founded 13 years ago, specialized in the sector Activités des agences de publicité. Based in PUTEAUX (92800), this company of category ETI shows in 2025 a revenue of 20.2 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE (SIREN 753922582)
Indicator 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue 20 166 632 € 16 261 224 € 7 528 826 € 11 387 059 € 5 051 470 € 5 157 503 € 5 527 754 € 5 502 084 € 6 333 047 € 3 565 814 €
Net income 530 639 € 362 369 € 120 835 € 140 272 € 121 935 € 118 759 € 119 577 € 55 687 € 113 668 € 143 830 €
EBITDA 621 931 € 438 257 € 145 193 € 160 015 € 187 853 € 182 285 € 228 566 € 295 998 € 197 136 € 90 000 €
Net margin 2.6% 2.2% 1.6% 1.2% 2.4% 2.3% 2.2% 1.0% 1.8% 4.0%

Revenue and income statement

In 2025, VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE achieves revenue of 20.2 M€. Over the period 2016-2025, the company shows strong growth with a CAGR (compound annual growth rate) of +21.2%. Vs 2024, growth of +24% (16.3 M€ -> 20.2 M€). After deducting consumption (8.1 M€), gross margin stands at 12.1 M€, i.e. a rate of 60%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 622 k€, representing 3.1% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 531 k€, i.e. 2.6% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2025) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

20 166 632 €

Gross margin (2025) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

12 082 064 €

EBITDA (2025) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

621 931 €

EBIT (2025) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

621 929 €

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

530 639 €

EBITDA margin (2025) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

3.1%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 132%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 16%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 4.6 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 2.6% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

131.895%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

16.294%

Cash flow / Revenue (2025) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

2.631%

Repayment capacity (2025) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

4.583

Solvency indicators evolution
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE

Sector positioning

Debt ratio
131.9 2025
2023
2024
2025
Q1: 0.04
Med: 9.23
Q3: 45.97
Watch

In 2025, the debt ratio of VIFOR FRESENIUS MEDICAL C... (131.90) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.

Financial autonomy
16.29% 2025
2023
2024
2025
Q1: 18.02%
Med: 39.91%
Q3: 65.06%
Average

In 2025, the financial autonomy of VIFOR FRESENIUS MEDICAL C... (16.3%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
4.58 years 2025
2023
2024
2025
Q1: 0.0 years
Med: 0.05 years
Q3: 1.72 years
Watch

In 2025, the repayment capacity of VIFOR FRESENIUS MEDICAL C... (4.58) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 99.47. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

99.468

Interest coverage (2025) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

0.0

Liquidity indicators evolution
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE

Sector positioning

Liquidity ratio
99.47 2025
2023
2024
2025
Q1: 140.75
Med: 218.9
Q3: 392.94
Watch -6 pts over 3 years

In 2025, the liquidity ratio of VIFOR FRESENIUS MEDICAL C... (99.47) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Interest coverage
0.0x 2025
2023
2024
2025
Q1: 0.0x
Med: 0.0x
Q3: 2.81x
Average

In 2025, the interest coverage of VIFOR FRESENIUS MEDICAL C... (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 58 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 115 days. Excellent situation: suppliers finance 57 days of the operating cycle (retail model). Overall, WCR represents 124 days of revenue, i.e. 6.9 M€ to permanently finance. Over 2016-2025, WCR increased by +525%, requiring additional financing.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

6 945 388 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

58 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

115 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2025) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

124 j

WCR and payment terms evolution
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE

Positioning of VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE in its sector

Comparison with sector Activités des agences de publicité

Valuation estimate

Based on 68 transactions of similar company sales (all years), the value of VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE is estimated at 2 560 542 € (range 969 091€ - 6 991 673€). With an EBITDA of 621 931€, the sector multiple of 2.9x is applied. The price/revenue ratio is 0.22x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2025
68 tx
969k€ 2560k€ 6991k€
2 560 542 € Range: 969 091€ - 6 991 673€
NAF 5 all-time

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
621 931 € × 2.9x
Estimation 1 786 850 €
515 646€ - 7 034 023€
Revenue Multiple 30%
20 166 632 € × 0.22x
Estimation 4 526 639 €
1 876 080€ - 7 705 225€
Net Income Multiple 20%
530 639 € × 2.9x
Estimation 1 545 631 €
742 220€ - 5 815 472€
How is this estimate calculated?

This estimate is based on the analysis of 68 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Activités des agences de publicité)

Compare VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE with other companies in the same sector:

Voir toutes les statistiques du secteur Activités des agences de publicité

Frequently asked questions about VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE

What is the revenue of VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE ?

The revenue of VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE in 2025 is 20.2 M€.

Is VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE profitable?

Yes, VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE generated a net profit of 531 k€ in 2025.

Where is the headquarters of VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE ?

The headquarters of VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE is located in PUTEAUX (92800), in the department Hauts-de-Seine.

Where to find the tax return of VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE ?

The tax return of VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE operate?

VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE operates in the sector Activités des agences de publicité (NAF code 73.11Z). See the 'Sector positioning' section above to compare the company with its competitors.